{"id":1628,"date":"2017-11-30T20:03:05","date_gmt":"2017-11-30T20:03:05","guid":{"rendered":"https:\/\/www.mybiosource.com\/learn\/?p=1628"},"modified":"2023-03-06T17:52:13","modified_gmt":"2023-03-06T17:52:13","slug":"sanofis-engineered-antibody-inches-closer-hiv-prevention-cure","status":"publish","type":"post","link":"https:\/\/www.mybiosource.com\/learn\/sanofis-engineered-antibody-inches-closer-hiv-prevention-cure\/","title":{"rendered":"Sanofi\u2019s Engineered Antibody Inches Closer to HIV Prevention and Cure"},"content":{"rendered":"

Table of Contents<\/strong><\/span><\/h2>\n

I. Introduction<\/strong>
\nII. Trispecific Antibody Confers Immunity from HIV-like Virus in Monkeys<\/strong>
\nIII. Collaborative Effort Between NIH and Sanofi<\/strong>
\nIV. Proprietary Technology of Sanofi<\/strong>
\nV. Comparative Study on Monkeys<\/strong>
\nVI. Manufacturing of Trispecific Antibody<\/strong>
\nVII. Phase 1 Trial to Test Safety and Pharmacokinetics<\/strong>
\nVIII. Study on HIV Infected People<\/strong>
\nIX. Engineered Antibodies for Treating Patients with Serious Ailments<\/strong>
\nX. Combination Therapies for HIV and Cancer<\/strong>
\nXI. Conclusion<\/strong><\/p>\n

\n

In a press statement released by National Institutes of Health (NIH<\/span>) on September 20, 2017, it was reported Sanofi\u2019s three-in-one antibody conferred immunity<\/span> from HIV<\/span>-like virus in monkeys. The collaborative effort between NIH<\/span> and France-based pharma major Sanofi achieved a significant milestone as the engineered antibodies (trispecific) stopped a greater number of HIV<\/span> strains from infecting cells in lab conditions compared with single effective antibodies. The trispecific antibody targets three different critical sites on HIV<\/span> strains, effectively countering the dodging mechanism of the virus. <\/em>
\nThe team now aims to conduct early-phase clinical trials<\/span> that aim to moderate the dosage level, study the effects of trispecific antibody, toxicities and side effects, and pharmacokinetics<\/span>. It is widely believed that the new trispecific antibody should be effective against HIV<\/span> compared with single antibodies. <\/em>
\nUsing proprietary technology of Sanofi, individually best performing HIV<\/span> antibodies such as VRC01, PGDM1400 and 10E8v4 are combined to achieve desirable outcomes in a clinical setting. In a comparative study conducted on monkeys, the trispecific antibody was found to be conferring immunity<\/span> in all six monkeys exposed to both \u2013 different strains of HIV<\/span> and trispecific antibody. However, monkeys administered with specific antibodies were found to be infected by strains of HIV<\/span>. <\/em>
\nSanofi is now manufacturing the trispecific antibody for use in Phase<\/span> 1 trial to test safety and pharmacokinetics<\/span> in healthy and ailing people. The study is expected to begin by late 2018. The study on HIV<\/span> infected people would be conducted separately with the help of NAID. <\/em>
\nFor some years now, the scientific community focused on infectious diseases, autoimmune<\/span> diseases and cancers believe engineered antibodies could be an effective way of treating patients with serious ailments. <\/em>
\nCombination therapies are already seen as effective in treating HIV<\/span> and Cancer. Engineered antibodies, if successful, would become a new class of focused drug agents and help in neutralizing challenges caused by the remarkable genetic diversity of viruses around the world.<\/em><\/p>\n

References<\/strong> <\/em>
\nhttps:\/\/www.nih.gov\/news-events\/news-releases\/three-one-antibody-protects-monkeys-hiv-virus<\/em><\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Table of Contents I. Introduction II. Trispecific Antibody Confers Immunity from HIV-like Virus in Monkeys III. Collaborative Effort Between NIH and Sanofi IV. Proprietary Technology of Sanofi V. Comparative Study on Monkeys VI. Manufacturing of Trispecific Antibody VII. Phase 1 Trial to Test Safety and Pharmacokinetics VIII. Study on HIV Infected People IX. Engineered Antibodies […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[1],"tags":[15,13,14],"class_list":["post-1628","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-antibody","tag-hiv","tag-sanofi"],"_links":{"self":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts\/1628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/comments?post=1628"}],"version-history":[{"count":0,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/posts\/1628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/media?parent=1628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/categories?post=1628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mybiosource.com\/learn\/wp-json\/wp\/v2\/tags?post=1628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}